Compounds > 1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol
Page last updated: 2024-08-26

1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol and Sarcoma

1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol has been researched along with Sarcoma in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adams, GE; Bedwell, J; Bown, SG; Bremner, JC; MacRobert, AJ; Pearson, JK; Phillips, D; Sansom, JM; Stratford, IJ1
Alliet, K; Maddison, K; Siemann, DW; Wolf, K1

Other Studies

2 other study(ies) available for 1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol and Sarcoma

ArticleYear
Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145.
    British journal of cancer, 1992, Volume: 66, Issue:6

    Topics: Animals; Indoles; Mice; Misonidazole; Nitroimidazoles; Organometallic Compounds; Photochemotherapy; Sarcoma; Tumor Cells, Cultured

1992
Enhancement of the antitumor efficacy of lomustine by the radiosensitizer RSU 1069.
    Cancer treatment reports, 1985, Volume: 69, Issue:12

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Lethal Dose 50; Lomustine; Mice; Mice, Inbred C3H; Misonidazole; Radiation-Protective Agents; Sarcoma

1985